Novo Nordisk Investor Presentation 2024. In the first nine months, we delivered 24% sales growth and 22% operating profit growth. Discover how novo nordisk's q1 2024 investor presentation highlights their progress towards strategic aspirations 2025 with a focus on diabetes and obesity care, financial performance,.
Read or listen to the conference call. In the first nine months, we delivered 24% sales growth and 22% operating profit growth.
Novo Nordisk Investor Presentation 2024 Images References :